Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: New allies for the treatment of patients with coronary artery disease

Fundamental and Clinical Pharmacology

Volumn 29, Issue 1, 2015, Pages 95-105

  Stojkovic, Sinisa ^a   Neskovic, Aleksandar N ^a   Mehmedbegovic, Zlatko ^a   Kafedzic, Srdjan ^a   Ostojic, Miodrag ^a   Nedeljkovic, Milan ^a   Orlic, Dejan ^a   Ilisic, Bojan ^a   Ilic, Ivan ^a   Aleksic, Aleksandar ^a   Cerovic, Milivoje ^a   Nikolajevic, Ivica ^a   Vlahovic Stipac, Alja ^a   Stajic, Zoran ^a   Putnikovic, Biljana ^a   Hamilos, Michalis ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

Bioresorbable co polymer; Drug eluting stent; Sirolimus

Indexed keywords

POLYMER; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG BLOOD LEVEL; DRUG ELUTING CORONARY STENT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST IN HUMAN STUDY; FOLLOW UP; HEART DISEASE; HUMAN; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; VASOMOTOR REFLEX; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG ELUTING STENT; METABOLISM; MIDDLE AGED; PROCEDURES; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERS; PROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84921065252     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12092     Document Type: Article

References (28)

1. Moses J.W., Leon M.B., Popma J.J. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. (2003) 349 1315-1323.
2. Stone G.W., Ellis S.G., Cox D.A. et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 109 1942-1947.
3. Fajadet J., Wijns W., Laarman G.J. et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation (2006) 114 798-806.
4. Chevalier B., Silber S., Park S.J. et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial - phase 2. Circ. Cardiovasc. Interv (2009) 2 188-195.
5. Stettler C., Wandel S., Allemann S. et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 370 937-948.
6. Camenzind E., Steg P.G., Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 115 1440-1455.
7. Stone G.W., Moses J.W., Ellis S.G. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. (2007) 356 998-1008.
8. Close S.L. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam. Clin. Pharmacol. (2012) 26 19-26.
9. Höchtl T., Tentzeris I., Schrör K., Huber K. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundam. Clin. Pharmacol. (2012) 26 2-10.
10. Virmani R., Guagliumi G., Farb A. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 109 701-705.
11. Van Beusekom H.M., Saia F., Zindler J.D. et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur. Heart J. (2007) 28 974-979.
12. Finn A.V., Nakazawa G., Joner M. et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. (2007) 27 1500-1510.
13. Togni M., Raber L., Cocchia R. et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int. J. Cardiol. (2007) 120 212-220.
14. Togni M., Windecker S., Cocchia R. et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. (2005) 46 231-236.
15. Hamilos M.I., Ostojic M., Beleslin B. et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol. (2008) 51 2123-2129.
16. Abizaid A., Costa J.R. Jr. Next-generation stent systems new drug-eluting stents: an overview on biodegradable and polymer-free. Circ. Cardiovasc. Interv. (2010) 3 384-393.
17. Terumo Corporation. Determination of Sirolimus in Human Blood - Pharmacokinetic study of TCD-10023 Terumo Drug Eluting Coronary Stent System (Protocol No. T117E4). JCL101182. 13-12-2011.
18. Vetrovec G.W., Rizik D., Williard C. et al. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc. Interv. (2006) 67 32-37.
19. Ostojic M.C., Perisic Z., Sagic D. et al. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study. Eur. J. Clin. Pharmacol. (2011) 67 389-398.
20. Ostojic M., Sagic D., Jung R. et al. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc. Interv. (2008) 72 901-908.
21. Otsuka Y., Saito S., Nakamura M. et al. Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. Catheter Cardiovasc. Interv. (2011) 78 1078-1085.
22. Serruys P.W., Ong A.T., Piek J.J. et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention (2005) 1 58-65.
23. Stojkovic S., Ostojic M., Nedeljkovic M. et al. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation. Catheter Cardiovasc. Intervent. (2010) 75 317-325.
24. Pendyala L.K., Matsumoto D., Shinke T. et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. JACC Cardiovasc. Interv. (2012) 5 436-444.
25. Rodriguez A.E., Granada J.F., Rodriguez-Alemparte M. et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) study. J. Am. Coll. Cardiol. (2006) 47 1522-1529.
26. Stefanini G.G., Byrne R.A., Serruys P.W. et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur. Heart J. (2012) 33 1214-1222.
27. Raber L., Wohlwend L., Wigger M. et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial. Circulation (2011) 123 2819-2828.
28. Byrne R.A., Kastrati A., Massberg S. et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. (2011) 58 1325-1331.